CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA
This article was originally published in The Tan Sheet
Executive Summary
CHPA says CBO's five-year $232m estimate for the costs of compliance with the DXM Abuse Prevention Act is too high since it is based on costs of FDA's tobacco compliance check program. CBO says the bill would have a minimal cost impact on retailers, since many already restrict sales.
You may also be interested in...
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.